Chikungunya virus (CHIKV) is a mosquito-borne alphavirus. As an emerging virus, CHIKV imposes a threat to public health. Currently, there are no vaccines or antivirals available for the prevention of CHIKV infection. Lycorine, an alkaloid from Amaryllidaceae plants, has antiviral activity against a number of viruses such as coronavirus, flavivirus and enterovirus. In this study, we found that lycorine could inhibit CHIKV in cell culture at a concentration of 10 μmol/L without apparent cytotoxicity. In addition, it exhibited broad-spectrum anti-alphavirus activity, including Sindbis virus (SINV), Semliki Forest virus (SFV), and Venezuelan equine encephalomyelitis virus (VEEV). The time of addition studies indicated that lycorine functions at an early post-entry stage of CHIKV life cycle. The results based on two different CHIKV replicons provided further evidence that lycorine exerts its antiviral activity mainly by inhibiting CHIKV translation. Overall, our study extends the antiviral spectrum of lycorine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353614 | PMC |
| http://dx.doi.org/10.1007/s12250-021-00438-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol for Screening Host-Targeting Antivirals (HTAs) Using Human PBMCs and pDCs.
Bio Protoc
March 2025
Tropical Infectious Disease Research and Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur, Malaysia.
This protocol offers an ex vivo method for screening host-targeting antivirals (HTAs) using human peripheral blood mononuclear cells (PBMCs) or plasmacytoid dendritic cells (pDCs). Unlike virus-targeting antivirals (VTAs), HTAs provide advantages in overcoming drug resistance and offering broad-spectrum protection, especially against rapidly mutating or newly emerging viruses. By focusing on PBMCs or pDCs, known for their high production of humoral factors such as Type I interferons (IFNs), the protocol enables the screening of antivirals that modulate immune responses against viruses.
View Article and Find Full Text PDFFull genomic sequence characterization of the chikungunya virus from an imported case with serum viral concentration below culturable level.
Biosaf Health
October 2024
Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510440, China.
Chikungunya virus (CHIKV) infection, responsible for chikungunya fever and occasionally severe symptoms, has emerged as an increasing global health concern following several large-scale outbreaks from Africa, Asia, Europe, and America. Over the past two decades, South and Southeast Asia regions have gradually become hot spots for outbreaks involving multiple CHIKV lineages. In China, most CHIKV infections are imported, making it crucial to trace the origins and transmission routes for effective prevention and control.
View Article and Find Full Text PDFMolecular and serological evidence of chikungunya virus among dengue suspected patients in Sri Lanka.
J Infect Public Health
February 2025
Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; Center for Vaccines and Therapeutic Antibodies for Emerging Infectious Diseases, Shimane University, Izumo 693-8501, Japan; Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; DEJIMA Infectious Disease Research Alliance, Nagasaki University, Japan. Electronic address:
Background: Chikungunya virus (CHIKV), transmitted by Aedes mosquitoes, causes significant morbidity characterized by acute febrile illness to chronic and permanent disability in some patients. Despite its potential for severe long-term effects, surveillance for CHIKV remains limited, especially in dengue-endemic region like Sri Lanka. To address the gap in surveillance, this study aimed to determine the prevalence of CHIKV among patients suspected of dengue fever during the 2017-2019 DENV outbreak in Sri Lanka.
View Article and Find Full Text PDFDifferential restriction of chikungunya virus in primary human cardiac endothelial cells occurs at multiple steps in the viral life cycle.
PLoS Negl Trop Dis
March 2025
Department of Microbiology, New York University Grossman School of Medicine, New York, New York, USA.
Arthropod-borne viruses (arboviruses) constitute a significant ongoing public health threat, as the mechanisms of pathogenesis remain incompletely understood. Cardiovascular symptomatology is emerging as an important manifestation of arboviral infection. We have recently studied the cardiac tropism implicated in cardiac infection in mice for the alphavirus chikungunya virus (CHIKV), and we therefore sought to evaluate the cardiac tropism of other emerging alphaviruses and arboviruses.
View Article and Find Full Text PDFExploring the potential of direct-acting antivirals against Chikungunya virus through structure-based drug repositioning and molecular dynamic simulations.
Comput Biol Med
March 2025
Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine & Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, 47500, Malaysia. Electronic address:
The Chikungunya virus (CHIKV) represents a significant global health threat, particularly in tropical regions, and no FDA-approved antiviral treatments are currently available. This study investigates the potential of Direct-Acting Antivirals (DAAs) and protease inhibitors (PIs) that have been developed for the hepatitis C virus (HCV) in treating CHIKV. We analyzed the binding of eight HCV DAAs to the nsP2 protease of CHIKV, which is essential for viral replication.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!